515 related articles for article (PubMed ID: 19164583)
1. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Li Y; Perry T; Kindy MS; Harvey BK; Tweedie D; Holloway HW; Powers K; Shen H; Egan JM; Sambamurti K; Brossi A; Lahiri DK; Mattson MP; Hoffer BJ; Wang Y; Greig NH
Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1285-90. PubMed ID: 19164583
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
Perry T; Lahiri DK; Sambamurti K; Chen D; Mattson MP; Egan JM; Greig NH
J Neurosci Res; 2003 Jun; 72(5):603-12. PubMed ID: 12749025
[TBL] [Abstract][Full Text] [Related]
3. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
4. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
6. The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.
Chen F; Wang W; Ding H; Yang Q; Dong Q; Cui M
J Neuroinflammation; 2016 Aug; 13(1):204. PubMed ID: 27566245
[TBL] [Abstract][Full Text] [Related]
7. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
Perry T; Haughey NJ; Mattson MP; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Sep; 302(3):881-8. PubMed ID: 12183643
[TBL] [Abstract][Full Text] [Related]
8. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
Jia Y; Gong N; Li TF; Zhu B; Wang YX
Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
[TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
10. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats.
Darsalia V; Mansouri S; Ortsäter H; Olverling A; Nozadze N; Kappe C; Iverfeldt K; Tracy LM; Grankvist N; Sjöholm Å; Patrone C
Clin Sci (Lond); 2012 May; 122(10):473-83. PubMed ID: 22150224
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling.
Mietlicki-Baase EG; Ortinski PI; Reiner DJ; Sinon CG; McCutcheon JE; Pierce RC; Roitman MF; Hayes MR
J Neurosci; 2014 May; 34(20):6985-92. PubMed ID: 24828651
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
16. An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
Zhang H; Liu Y; Guan S; Qu D; Wang L; Wang X; Li X; Zhou S; Zhou Y; Wang N; Meng J; Ma X
PLoS One; 2016; 11(2):e0148827. PubMed ID: 26863436
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.
DeNicola M; Du J; Wang Z; Yano N; Zhang L; Wang Y; Qin G; Zhuang S; Zhao TC
Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E630-43. PubMed ID: 25117407
[TBL] [Abstract][Full Text] [Related]
18. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
[TBL] [Abstract][Full Text] [Related]
19. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
Burmeister MA; Ayala J; Drucker DJ; Ayala JE
Am J Physiol Endocrinol Metab; 2013 Apr; 304(7):E677-85. PubMed ID: 23341495
[TBL] [Abstract][Full Text] [Related]
20. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia.
Lee CH; Yan B; Yoo KY; Choi JH; Kwon SH; Her S; Sohn Y; Hwang IK; Cho JH; Kim YM; Won MH
J Neurosci Res; 2011 Jul; 89(7):1103-13. PubMed ID: 21472764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
